Caris Life Sciences, Inc. reported significant financial growth in its latest quarterly filing, with total revenue reaching $216.2 million for the three months ended March 31, 2026, compared to $120.9 million for the same period in 2025, marking a 78.8% increase. The company's molecular profiling services, which accounted for the majority of revenue, surged to $210.8 million, up 84.8% from $114.1 million year-over-year. This growth was primarily driven by increased clinical case volumes and higher reimbursement rates, particularly following the launch of the MI Cancer Seek solution. The company also reported a net loss of $0.5 million, a significant improvement from a net loss of $102.6 million in the prior year.
In terms of operational metrics, Caris reported an increase in clinical cases, with 52,800 cases processed in the first quarter of 2026 compared to 45,900 in the same quarter of 2025. The company’s average selling price for its MI Profile platform also increased, contributing to the overall revenue growth. However, revenue from pharma research and development services decreased by 21.4% to $5.4 million, attributed to the timing of service deliveries under existing agreements.
Caris has made strategic investments to enhance its operational capabilities, including expanding its laboratory capacity and increasing its workforce. As of March 31, 2026, the company had cash, cash equivalents, and marketable securities totaling $825.7 million, which it believes will support its operational needs for at least the next 12 months. The company also reported a total of 1,162 employees, reflecting its ongoing efforts to scale operations in response to growing demand for its services.
The company’s financial position was further strengthened by the recent repayment of its 2023 Term Loan, which was fully paid off on April 1, 2026, as part of a new financing agreement that provides for additional credit facilities. This new agreement includes a $400 million initial term loan and a $300 million delayed draw term loan, aimed at supporting future acquisitions and operational growth. Looking ahead, Caris anticipates continued investment in research and development, marketing, and infrastructure to drive further adoption of its precision medicine solutions, while also navigating the complexities of payer reimbursement and market acceptance.
About Caris Life Sciences, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.